索引于
- 学术期刊数据库
- 打开 J 门
- Genamics 期刊搜索
- 学术钥匙
- 期刊目录
- 中国知网（CNKI）
- 引用因子
- 西马戈
- 乌尔里希的期刊目录
- 电子期刊图书馆
- 参考搜索
- 哈姆达大学
- 亚利桑那州EBSCO
- OCLC-WorldCat
- SWB 在线目录
- 虚拟生物学图书馆 (vifabio)
- 普布隆斯
- 米亚尔
- 大学教育资助委员会
- 日内瓦医学教育与研究基金会
- 欧洲酒吧
- 谷歌学术
分享此页面
期刊传单
抽象的
Bioequivalence Study of Quetiapine 25 mg Tablets in Healthy Thai Volunteers under Fasting Conditions
Ekawan Yoosakul, Vipada Khaowroongrueng, Jaturavit Vattanarongkup, Charinthon Seeduang, Nava Suthepakul, Busarat Karachot, Isariya Techatanawat, Praphassorn Surawattanawan, Porranee Puranajoti
A comparative randomized, single-dose, two-way crossover, open-label study was carried out to assess bioequivalence and tolerability of test (Quapine®) and reference (Seroquel®) products of quetiapine 25 mg tablets in healthy Thai volunteers. Forty-four male and female subjects were enrolled in the study. Blood samples were collected at predefined time points over 48 hours after oral administration. Plasma concentrations of quetiapine were determined using a validated Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). The pharmacokinetic parameters were calculated for the test and reference products using non-compartmental analysis. Bioequivalence between the products was determined by calculating 90% Confidence Intervals (CIs) for the geometric least squares mean ratio of log-transformed primary parameters (AUC0-tlast, AUC0-∞ and Cmax) between the test and reference products. The 90% CIs were 96.08%-108.33% for AUC0-tlast, 96.21%-108.31% for AUC0-∞ and 96.52%-121.09% for Cmax which were within the bioequivalence criteria of 80.00%-125.00%. The analysis of variance did not show any significant difference between the two formulations. Both formulations were generally well tolerated in Thai subjects. The incidence of adverse events after receiving the test and reference products was similar. Therefore, they can be used interchangeably, and the same efficacy and safety can be anticipated.